MetaVia (NASDAQ:MTVA) Posts Quarterly Earnings Results, Beats Estimates By $0.25 EPS

MetaVia (NASDAQ:MTVA) posted its quarterly earnings results on Friday. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.25, FiscalAI reports.

MetaVia Trading Up 3.1%

Shares of MTVA stock traded up $0.04 on Friday, hitting $1.34. The stock had a trading volume of 34,453 shares, compared to its average volume of 1,228,392. MetaVia has a twelve month low of $0.97 and a twelve month high of $13.42. The firm has a market cap of $6.91 million, a P/E ratio of -0.41 and a beta of 1.24. The company has a fifty day moving average price of $1.47 and a two-hundred day moving average price of $1.62.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of MetaVia in a research note on Monday, October 19th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $20.00.

About MetaVia

MetaVia, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. Its work is centered on conditions such as obesity, diabetes and other disorders associated with metabolic dysfunction. The company’s activities primarily involve the discovery, development and clinical evaluation of potential drug candidates intended to address significant unmet medical needs in metabolic health. As a development-stage biotechnology company, MetaVia’s operations are focused on research programs and advancing therapies through clinical testing rather than on commercialized products.